Drug intelligence / Profile preview

MCT-SR

Development stage: Unknown
Lead developer: Otsuka Holdings
Modality: Small Molecules
Administration: Oral

Overview

MCT-SR is a sustained-release (SR) formulation of rebamipide developed to improve treatment compliance and patient convenience in the management of gastritis. Rebamipide is a gastroprotective agent that promotes mucosal defense, healing, and repair by increasing prostaglandin production, scavenging free radicals, and enhancing mucus secretion in the gastrointestinal tract. The SR formulation allows for less frequent dosing compared to immediate-release forms. MCT-SR has been evaluated in phase 3 clinical trials for efficacy and safety in patients with acute or chronic gastritis[2].

Brand names: MCT-SR

Targets

COX

Beyond the preview

Go deeper on MCT-SR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCT-SR.

Explore the full profile